000172312812-312023Q2false00017231282023-01-012023-06-300001723128us-gaap:CommonClassAMember2023-07-31xbrli:shares0001723128us-gaap:CommonClassBMember2023-07-3100017231282023-04-012023-06-30iso4217:USD00017231282022-04-012022-06-3000017231282022-01-012022-06-30iso4217:USDxbrli:shares00017231282023-06-3000017231282022-12-310001723128us-gaap:NonrelatedPartyMember2023-06-300001723128us-gaap:NonrelatedPartyMember2022-12-310001723128us-gaap:RelatedPartyMember2023-06-300001723128us-gaap:RelatedPartyMember2022-12-310001723128us-gaap:CommonClassAMember2023-06-300001723128us-gaap:CommonClassAMember2022-12-310001723128us-gaap:CommonClassBMember2022-12-310001723128us-gaap:CommonClassBMember2023-06-3000017231282021-12-3100017231282022-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-03-310001723128us-gaap:AdditionalPaidInCapitalMember2023-03-310001723128us-gaap:RetainedEarningsMember2023-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001723128us-gaap:NoncontrollingInterestMember2023-03-3100017231282023-03-310001723128us-gaap:RetainedEarningsMember2023-04-012023-06-300001723128us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001723128us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-012023-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-06-300001723128us-gaap:AdditionalPaidInCapitalMember2023-06-300001723128us-gaap:RetainedEarningsMember2023-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001723128us-gaap:NoncontrollingInterestMember2023-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001723128us-gaap:AdditionalPaidInCapitalMember2022-12-310001723128us-gaap:RetainedEarningsMember2022-12-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001723128us-gaap:NoncontrollingInterestMember2022-12-310001723128us-gaap:RetainedEarningsMember2023-01-012023-06-300001723128us-gaap:NoncontrollingInterestMember2023-01-012023-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001723128us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-03-310001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-03-310001723128us-gaap:AdditionalPaidInCapitalMember2022-03-310001723128us-gaap:RetainedEarningsMember2022-03-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001723128us-gaap:NoncontrollingInterestMember2022-03-3100017231282022-03-310001723128us-gaap:RetainedEarningsMember2022-04-012022-06-300001723128us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001723128us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-04-012022-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-06-300001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001723128us-gaap:AdditionalPaidInCapitalMember2022-06-300001723128us-gaap:RetainedEarningsMember2022-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001723128us-gaap:NoncontrollingInterestMember2022-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001723128us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001723128us-gaap:AdditionalPaidInCapitalMember2021-12-310001723128us-gaap:RetainedEarningsMember2021-12-310001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001723128us-gaap:NoncontrollingInterestMember2021-12-310001723128us-gaap:RetainedEarningsMember2022-01-012022-06-300001723128us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001723128us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001723128us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001723128us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-06-300001723128amrx:AmnealGroupMember2023-06-30xbrli:pure0001723128amrx:AmnealGroupMemberamrx:AmnealGroupMember2023-06-300001723128amrx:SaolBaclofenFranchiseAcquisitionMember2022-02-092022-02-090001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001723128amrx:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2023-04-012023-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2022-04-012022-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2023-01-012023-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2022-01-012022-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2023-04-012023-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2022-04-012022-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2023-01-012023-06-300001723128us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2022-01-012022-06-300001723128amrx:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001723128amrx:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001723128amrx:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001723128amrx:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:AntiInfectiveMember2023-04-012023-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:AntiInfectiveMember2022-04-012022-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:AntiInfectiveMember2023-01-012023-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:AntiInfectiveMember2022-01-012022-06-300001723128amrx:HormonalAllergyMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:HormonalAllergyMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:HormonalAllergyMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:HormonalAllergyMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:AntiviralMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:AntiviralMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:AntiviralMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:AntiviralMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:CentralNervousSystemMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:CentralNervousSystemMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:CentralNervousSystemMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:CentralNervousSystemMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:GenericsSegmentMemberamrx:CardiovascularSystemMembercountry:US2023-04-012023-06-300001723128amrx:GenericsSegmentMemberamrx:CardiovascularSystemMembercountry:US2022-04-012022-06-300001723128amrx:GenericsSegmentMemberamrx:CardiovascularSystemMembercountry:US2023-01-012023-06-300001723128amrx:GenericsSegmentMemberamrx:CardiovascularSystemMembercountry:US2022-01-012022-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:GastroenterologyMember2023-04-012023-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:GastroenterologyMember2022-04-012022-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:GastroenterologyMember2023-01-012023-06-300001723128amrx:GenericsSegmentMembercountry:USamrx:GastroenterologyMember2022-01-012022-06-300001723128amrx:OncologyMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:OncologyMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:OncologyMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:OncologyMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:GenericsSegmentMemberamrx:MetabolicDiseaseEndocrineMembercountry:US2023-04-012023-06-300001723128amrx:GenericsSegmentMemberamrx:MetabolicDiseaseEndocrineMembercountry:US2022-04-012022-06-300001723128amrx:GenericsSegmentMemberamrx:MetabolicDiseaseEndocrineMembercountry:US2023-01-012023-06-300001723128amrx:GenericsSegmentMemberamrx:MetabolicDiseaseEndocrineMembercountry:US2022-01-012022-06-300001723128amrx:RespiratoryMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:RespiratoryMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:RespiratoryMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:RespiratoryMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:DermatologyMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:DermatologyMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:DermatologyMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:DermatologyMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:GenericsSegmentMembercountry:US2023-04-012023-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:GenericsSegmentMembercountry:US2022-04-012022-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:GenericsSegmentMembercountry:US2023-01-012023-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:GenericsSegmentMembercountry:US2022-01-012022-06-300001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2023-04-012023-06-300001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2022-04-012022-06-300001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2023-01-012023-06-300001723128us-gaap:NonUsMemberamrx:GenericsSegmentMember2022-01-012022-06-300001723128amrx:GenericsSegmentMember2023-04-012023-06-300001723128amrx:GenericsSegmentMember2022-04-012022-06-300001723128amrx:GenericsSegmentMember2023-01-012023-06-300001723128amrx:GenericsSegmentMember2022-01-012022-06-300001723128amrx:HormonalAllergyMemberamrx:SpecialtySegmentMembercountry:US2023-04-012023-06-300001723128amrx:HormonalAllergyMemberamrx:SpecialtySegmentMembercountry:US2022-04-012022-06-300001723128amrx:HormonalAllergyMemberamrx:SpecialtySegmentMembercountry:US2023-01-012023-06-300001723128amrx:HormonalAllergyMemberamrx:SpecialtySegmentMembercountry:US2022-01-012022-06-300001723128amrx:CentralNervousSystemMemberamrx:SpecialtySegmentMembercountry:US2023-04-012023-06-300001723128amrx:CentralNervousSystemMemberamrx:SpecialtySegmentMembercountry:US2022-04-012022-06-300001723128amrx:CentralNervousSystemMemberamrx:SpecialtySegmentMembercountry:US2023-01-012023-06-300001723128amrx:CentralNervousSystemMemberamrx:SpecialtySegmentMembercountry:US2022-01-012022-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMembercountry:US2023-04-012023-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMembercountry:US2022-04-012022-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMembercountry:US2023-01-012023-06-300001723128amrx:OtherTherapeuticClassesMemberamrx:SpecialtySegmentMembercountry:US2022-01-012022-06-300001723128amrx:SpecialtySegmentMember2023-04-012023-06-300001723128amrx:SpecialtySegmentMember2022-04-012022-06-300001723128amrx:SpecialtySegmentMember2023-01-012023-06-300001723128amrx:SpecialtySegmentMember2022-01-012022-06-300001723128amrx:AvKARESegmentMembercountry:USus-gaap:DistributionServiceMember2023-04-012023-06-300001723128amrx:AvKARESegmentMembercountry:USus-gaap:DistributionServiceMember2022-04-012022-06-300001723128amrx:AvKARESegmentMembercountry:USus-gaap:DistributionServiceMember2023-01-012023-06-300001723128amrx:AvKARESegmentMembercountry:USus-gaap:DistributionServiceMember2022-01-012022-06-300001723128amrx:GovernmentLabelMemberamrx:AvKARESegmentMembercountry:US2023-04-012023-06-300001723128amrx:GovernmentLabelMemberamrx:AvKARESegmentMembercountry:US2022-04-012022-06-300001723128amrx:GovernmentLabelMemberamrx:AvKARESegmentMembercountry:US2023-01-012023-06-300001723128amrx:GovernmentLabelMemberamrx:AvKARESegmentMembercountry:US2022-01-012022-06-300001723128amrx:InstitutionalMemberamrx:AvKARESegmentMembercountry:US2023-04-012023-06-300001723128amrx:InstitutionalMemberamrx:AvKARESegmentMembercountry:US2022-04-012022-06-300001723128amrx:InstitutionalMemberamrx:AvKARESegmentMembercountry:US2023-01-012023-06-300001723128amrx:InstitutionalMemberamrx:AvKARESegmentMembercountry:US2022-01-012022-06-300001723128amrx:AvKARESegmentMemberus-gaap:ProductAndServiceOtherMembercountry:US2023-04-012023-06-300001723128amrx:AvKARESegmentMemberus-gaap:ProductAndServiceOtherMembercountry:US2022-04-012022-06-300001723128amrx:AvKARESegmentMemberus-gaap:ProductAndServiceOtherMembercountry:US2023-01-012023-06-300001723128amrx:AvKARESegmentMemberus-gaap:ProductAndServiceOtherMembercountry:US2022-01-012022-06-300001723128amrx:AvKARESegmentMember2023-04-012023-06-300001723128amrx:AvKARESegmentMember2022-04-012022-06-300001723128amrx:AvKARESegmentMember2023-01-012023-06-300001723128amrx:AvKARESegmentMember2022-01-012022-06-300001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2022-12-310001723128amrx:CashDiscountAllowancesMember2022-12-310001723128us-gaap:SalesReturnsAndAllowancesMember2022-12-310001723128amrx:AccruedMedicaidAndCommercialRebatesMember2022-12-310001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2023-01-012023-06-300001723128amrx:CashDiscountAllowancesMember2023-01-012023-06-300001723128us-gaap:SalesReturnsAndAllowancesMember2023-01-012023-06-300001723128amrx:AccruedMedicaidAndCommercialRebatesMember2023-01-012023-06-300001723128amrx:ContractChargebacksAndSalesVolumeAllowancesMember2023-06-300001723128amrx:CashDiscountAllowancesMember2023-06-300001723128us-gaap:SalesReturnsAndAllowancesMember2023-06-300001723128amrx:AccruedMedicaidAndCommercialRebatesMember2023-06-300001723128amrx:LicenseAgreementWithOrionCorporationMember2022-12-282022-12-28iso4217:EUR0001723128amrx:LicenseAgreementWithOrionCorporationMember2023-06-302023-06-300001723128amrx:LicenseAgreementWithOrionCorporationMember2022-01-012022-12-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2022-12-310001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001723128amrx:LicenseAgreementWithOrionCorporationMember2023-01-012023-06-300001723128amrx:LicenseAgreementWithOrionCorporationMember2023-04-012023-06-300001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-06-300001723128amrx:LicenseAgreementWithOrionCorporationMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-06-300001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2018-05-072018-05-0700017231282022-01-012022-12-310001723128amrx:BiosimilarLicensingAndSupplyAgreementMember2022-12-310001723128amrx:GovernmentOfIndiaMember2021-11-30amrx:companyiso4217:INR0001723128amrx:GovernmentOfIndiaMember2023-06-300001723128amrx:GovernmentOfIndiaMember2021-11-012021-11-300001723128amrx:GovernmentOfIndiaMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-06-300001723128amrx:GovernmentOfIndiaMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-3100017231282019-12-310001723128srt:ScenarioForecastMember2023-07-012023-08-090001723128us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001723128us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001723128us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001723128us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001723128us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001723128us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001723128us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001723128us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001723128us-gaap:PerformanceSharesMember2023-04-012023-06-300001723128us-gaap:PerformanceSharesMember2022-04-012022-06-300001723128us-gaap:PerformanceSharesMember2023-01-012023-06-300001723128us-gaap:PerformanceSharesMember2022-01-012022-06-300001723128us-gaap:CommonClassBMember2023-04-012023-06-300001723128us-gaap:CommonClassBMember2022-04-012022-06-300001723128us-gaap:CommonClassBMember2023-01-012023-06-300001723128us-gaap:CommonClassBMember2022-01-012022-06-300001723128us-gaap:AccountsReceivableMemberamrx:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001723128us-gaap:AccountsReceivableMemberamrx:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001723128us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2023-01-012023-06-300001723128us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerBMember2022-01-012022-12-310001723128us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2023-01-012023-06-300001723128us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberamrx:CustomerCMember2022-01-012022-12-310001723128us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberamrx:LicenseAgreementWithOrionCorporationMember2022-12-310001723128amrx:SpecialtySegmentMember2023-06-300001723128amrx:GenericsSegmentMember2023-06-300001723128amrx:AvKARESegmentMember2023-06-300001723128amrx:SpecialtySegmentMember2022-12-310001723128amrx:GenericsSegmentMember2022-12-310001723128amrx:AvKARESegmentMember2022-12-310001723128us-gaap:ContractualRightsMember2023-06-300001723128us-gaap:ContractualRightsMember2022-12-310001723128us-gaap:TradeNamesMember2023-06-300001723128us-gaap:TradeNamesMember2022-12-310001723128amrx:IPX203InProcessResearchAndDevelopmentMemberus-gaap:MeasurementInputDiscountRateMember2023-01-012023-06-300001723128amrx:IPX203InProcessResearchAndDevelopmentMember2023-06-300001723128us-gaap:MeasurementInputLongTermRevenueGrowthRateMember2023-01-012023-06-300001723128us-gaap:MeasurementInputDiscountRateMember2023-01-012023-06-300001723128us-gaap:InterestRateSwapMember2023-06-300001723128us-gaap:InterestRateSwapMember2022-12-310001723128amrx:SecurityDepositsMember2023-06-300001723128amrx:SecurityDepositsMember2022-12-310001723128amrx:LongTermPrepaidExpensesMember2023-06-300001723128amrx:LongTermPrepaidExpensesMember2022-12-310001723128amrx:DeferredRevolvingCreditFacilityCostsMember2023-06-300001723128amrx:DeferredRevolvingCreditFacilityCostsMember2022-12-310001723128us-gaap:OtherNoncurrentAssetsMember2023-06-300001723128us-gaap:OtherNoncurrentAssetsMember2022-12-310001723128amrx:TermLoanDueMay2025Member2023-06-300001723128amrx:TermLoanDueMay2025Member2022-12-310001723128amrx:RondoTermLoanDueJanuaryTwoThousandTwentyFiveMember2023-06-300001723128amrx:RondoTermLoanDueJanuaryTwoThousandTwentyFiveMember2022-12-310001723128us-gaap:RevolvingCreditFacilityMember2023-01-310001723128amrx:OpanaERAntitrustLitigationMember2023-01-012023-01-310001723128us-gaap:RevolvingCreditFacilityMember2023-03-012023-03-310001723128us-gaap:RevolvingCreditFacilityMember2023-06-300001723128amrx:RondoTermLoanMember2023-04-012023-06-300001723128amrx:RondoTermLoanMember2023-01-012023-06-300001723128amrx:RondoTermLoanMember2023-06-300001723128amrx:SecuredOvernightFinancingRateSOFRMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-05-312023-05-310001723128amrx:SecuredOvernightFinancingRateSOFRMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-05-310001723128amrx:SecuredOvernightFinancingRateSOFRMemberus-gaap:SecuredDebtMemberamrx:RondoRevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-04-202023-04-200001723128amrx:UncertainTaxPositionNoncurrentMember2023-06-300001723128amrx:UncertainTaxPositionNoncurrentMember2022-12-310001723128amrx:LongTermPortionOfLiabilitiesForLegalMattersMember2023-06-300001723128amrx:LongTermPortionOfLiabilitiesForLegalMattersMember2022-12-310001723128amrx:LongTermCompensationMember2023-06-300001723128amrx:LongTermCompensationMember2022-12-310001723128amrx:ContingentConsiderationMember2023-06-300001723128amrx:ContingentConsiderationMember2022-12-310001723128us-gaap:OtherNoncurrentLiabilitiesMember2023-06-300001723128us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001723128us-gaap:FairValueInputsLevel1Member2023-06-300001723128us-gaap:FairValueInputsLevel2Member2023-06-300001723128us-gaap:FairValueInputsLevel3Member2023-06-300001723128us-gaap:FairValueInputsLevel1Member2022-12-310001723128us-gaap:FairValueInputsLevel2Member2022-12-310001723128us-gaap:FairValueInputsLevel3Member2022-12-310001723128amrx:AccountsPayableAndAccruedExpensesMemberamrx:SaolBaclofenFranchiseAcquisitionMember2023-06-300001723128amrx:AccountsPayableAndAccruedExpensesMemberamrx:SaolBaclofenFranchiseAcquisitionMember2022-12-310001723128amrx:SaolBaclofenFranchiseAcquisitionMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-06-300001723128amrx:SaolBaclofenFranchiseAcquisitionMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001723128amrx:KashivSpecialtyPharmaceuticalsLLCMember2023-06-300001723128amrx:KashivSpecialtyPharmaceuticalsLLCMember2022-12-310001723128amrx:KashivSpecialtyPharmaceuticalsLLCMember2021-04-020001723128amrx:SaolBaclofenFranchiseAndKashivSpecialtyPharmaceuticalsLLCMember2023-01-012023-06-300001723128amrx:RoyaltiesSaolAcquisitionMember2023-06-300001723128srt:MinimumMemberamrx:RoyaltiesSaolAcquisitionMemberus-gaap:MeasurementInputDiscountRateMember2023-06-300001723128amrx:RoyaltiesSaolAcquisitionMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2023-06-300001723128amrx:RoyaltiesSaolAcquisitionMemberus-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2023-06-300001723128us-gaap:FairValueInputsLevel2Memberus-gaap:MediumTermNotesMember2023-06-300001723128us-gaap:FairValueInputsLevel2Memberus-gaap:MediumTermNotesMember2022-12-310001723128us-gaap:FairValueInputsLevel2Memberamrx:RondoPartnersLLCMemberus-gaap:MediumTermNotesMember2023-06-300001723128us-gaap:FairValueInputsLevel2Memberamrx:RondoPartnersLLCMemberus-gaap:MediumTermNotesMember2022-12-310001723128amrx:LongTermPromissoryNotesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001723128amrx:LongTermPromissoryNotesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001723128amrx:InterestRateLockAgreementMember2019-10-310001723128us-gaap:OtherAssetsMemberamrx:VariableToFixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300001723128us-gaap:OtherAssetsMemberamrx:VariableToFixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001723128amrx:OpanaERAntitrustLitigationMember2023-06-300001723128amrx:OpanaERAntitrustLitigationMember2022-12-310001723128amrx:OpanaERAccruedInterestMember2023-06-300001723128amrx:OpanaERAccruedInterestMember2022-12-310001723128amrx:OpanaERImputedInterestMember2023-06-300001723128amrx:OpanaERImputedInterestMember2022-12-310001723128amrx:CivilPrescriptionOpioidLitigationMember2023-06-300001723128amrx:CivilPrescriptionOpioidLitigationMember2022-12-310001723128amrx:OtherMember2023-06-300001723128amrx:OtherMember2022-12-310001723128amrx:PrescriptionOpioidLitigationMember2023-06-300001723128amrx:PrescriptionOpioidLitigationMember2022-12-310001723128amrx:OpanaERAntitrustLitigationMember2022-06-300001723128amrx:OpanaERAntitrustLitigationMember2023-01-012023-06-300001723128amrx:AmountDueOnDecember2022AndMidJanuary2024Member2023-06-300001723128amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember2014-11-062014-11-06amrx:representative0001723128amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember2015-03-132015-03-13amrx:medication0001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2019-05-10amrx:state0001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2019-11-010001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2020-06-100001723128amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2022-03-302022-03-30amrx:lawsuit0001723128us-gaap:SubsequentEventMemberamrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember2023-07-012023-07-01amrx:complaintamrx:case0001723128amrx:CivilPrescriptionOpioidLitigationMember2023-05-302023-05-30amrx:product0001723128amrx:CivilPrescriptionOpioidLitigationMember2022-01-012022-12-310001723128amrx:CivilPrescriptionOpioidLitigationMember2023-04-012023-06-300001723128amrx:CivilPrescriptionOpioidLitigationMember2023-01-012023-06-300001723128amrx:ValueDrugCompanyVTakedaPharmaceuticalsUSAIncMember2023-04-10amrx:plaintiff00017231282022-03-222022-03-220001723128us-gaap:SubsequentEventMemberamrx:RussellThieleEtAlVKashivBiosciencesLLCEtAlMember2023-07-272023-07-270001723128amrx:AmnealPharmaceuticalsInc2018IncentiveAwardPlanMember2023-05-092023-05-090001723128amrx:AmnealPharmaceuticalsInc2018IncentiveAwardPlanMember2023-05-090001723128amrx:SellersOfKSPMemberamrx:KashivSpecialtyPharmaceuticalsLLCMember2021-04-020001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2020-12-310001723128amrx:RondoPartnersLLCMemberamrx:AvKareIncorporationAndRAndSNortheastLLCMember2020-01-310001723128amrx:RondoPartnersLLCMemberamrx:AvKareIncorporationAndRAndSNortheastLLCMember2023-06-300001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2023-04-012023-06-300001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2023-01-012023-06-300001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2022-04-012022-06-300001723128amrx:AvKareIncorporationAndRAndSNortheastLLCMember2022-01-012022-06-300001723128amrx:PuniskaMember2021-11-020001723128amrx:PuniskaMember2023-06-300001723128amrx:PuniskaMember2022-03-012022-03-310001723128amrx:PuniskaMember2022-03-310001723128amrx:PuniskaMember2022-01-012022-06-300001723128us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001723128us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-06-300001723128us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001723128us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentParkingSpaceLeaseMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentParkingSpaceLeaseMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentParkingSpaceLeaseMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentParkingSpaceLeaseMember2022-01-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:SellingGeneralAndAdministrativeDevelopmentAndCommercializationAgreementMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:SellingGeneralAndAdministrativeDevelopmentAndCommercializationAgreementMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:SellingGeneralAndAdministrativeDevelopmentAndCommercializationAgreementMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:SellingGeneralAndAdministrativeDevelopmentAndCommercializationAgreementMember2022-01-012022-06-300001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2023-04-012023-06-300001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2022-04-012022-06-300001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2023-01-012023-06-300001723128amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementGanirelixAcetateAndCentrorelixAcetateMemberamrx:KashivBioSciencesLLCMember2022-01-012022-06-300001723128amrx:IntangibleAssetLicenseAndCommercializationAgreementMemberamrx:KashivBioSciencesLLCMember2023-04-012023-06-300001723128amrx:IntangibleAssetLicenseAndCommercializationAgreementMemberamrx:KashivBioSciencesLLCMember2022-04-012022-06-300001723128amrx:IntangibleAssetLicenseAndCommercializationAgreementMemberamrx:KashivBioSciencesLLCMember2023-01-012023-06-300001723128amrx:IntangibleAssetLicenseAndCommercializationAgreementMemberamrx:KashivBioSciencesLLCMember2022-01-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimMember2022-01-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:ResearchAndDevelopmentStorageIncomeMember2022-01-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-01-012022-06-300001723128amrx:KashivBioSciencesLLCMember2023-04-012023-06-300001723128amrx:KashivBioSciencesLLCMember2022-04-012022-06-300001723128amrx:KashivBioSciencesLLCMember2023-01-012023-06-300001723128amrx:KashivBioSciencesLLCMember2022-01-012022-06-300001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2023-04-012023-06-300001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2022-04-012022-06-300001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2023-01-012023-06-300001723128amrx:InventoryAndCostOfGoodsSoldMemberamrx:KananLLCMember2022-01-012022-06-300001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-04-012023-06-300001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-04-012022-06-300001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-06-300001723128amrx:SutariaFamilyRealtyLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-01-012022-06-300001723128amrx:PharmaSophiaLLCMemberamrx:ResearchAndDevelopmentMember2023-04-012023-06-300001723128amrx:PharmaSophiaLLCMemberamrx:ResearchAndDevelopmentMember2022-04-012022-06-300001723128amrx:PharmaSophiaLLCMemberamrx:ResearchAndDevelopmentMember2023-01-012023-06-300001723128amrx:PharmaSophiaLLCMemberamrx:ResearchAndDevelopmentMember2022-01-012022-06-300001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-04-012023-06-300001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-04-012022-06-300001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-06-300001723128amrx:ApaceKYLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-01-012022-06-300001723128amrx:TracyPropertiesLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2023-04-012023-06-300001723128amrx:TracyPropertiesLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2022-04-012022-06-300001723128amrx:TracyPropertiesLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2023-01-012023-06-300001723128amrx:TracyPropertiesLLCMemberamrx:SellingGeneralAndAdministrativeOperatingLeaseMember2022-01-012022-06-300001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-04-012023-06-300001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-04-012022-06-300001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-06-300001723128amrx:AzaTechPharmaLLCMemberamrx:InventoryAndCostOfGoodsSoldMember2022-01-012022-06-300001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:AvPropLLCMember2023-04-012023-06-300001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:AvPropLLCMember2022-04-012022-06-300001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:AvPropLLCMember2023-01-012023-06-300001723128amrx:SellingGeneralAndAdministrativeOperatingLeaseMemberamrx:AvPropLLCMember2022-01-012022-06-300001723128amrx:ResearchAndDevelopmentMemberamrx:AvtarInvestmentsLLCMember2023-04-012023-06-300001723128amrx:ResearchAndDevelopmentMemberamrx:AvtarInvestmentsLLCMember2022-04-012022-06-300001723128amrx:ResearchAndDevelopmentMemberamrx:AvtarInvestmentsLLCMember2023-01-012023-06-300001723128amrx:ResearchAndDevelopmentMemberamrx:AvtarInvestmentsLLCMember2022-01-012022-06-300001723128amrx:SellingGeneralAndAdministrativeConsultingServicesMemberamrx:TPGOperationsLLCMember2023-04-012023-06-300001723128amrx:SellingGeneralAndAdministrativeConsultingServicesMemberamrx:TPGOperationsLLCMember2022-04-012022-06-300001723128amrx:SellingGeneralAndAdministrativeConsultingServicesMemberamrx:TPGOperationsLLCMember2023-01-012023-06-300001723128amrx:SellingGeneralAndAdministrativeConsultingServicesMemberamrx:TPGOperationsLLCMember2022-01-012022-06-300001723128amrx:AlkermesPlcMemberamrx:InventoryAndCostOfGoodsSoldMember2023-04-012023-06-300001723128amrx:AlkermesPlcMemberamrx:InventoryAndCostOfGoodsSoldMember2022-04-012022-06-300001723128amrx:AlkermesPlcMemberamrx:InventoryAndCostOfGoodsSoldMember2023-01-012023-06-300001723128amrx:AlkermesPlcMemberamrx:InventoryAndCostOfGoodsSoldMember2022-01-012022-06-300001723128amrx:SellingGeneralAndAdministrativeLogisticsServicesMemberamrx:RSSolutionsMember2023-04-012023-06-300001723128amrx:SellingGeneralAndAdministrativeLogisticsServicesMemberamrx:RSSolutionsMember2022-04-012022-06-300001723128amrx:SellingGeneralAndAdministrativeLogisticsServicesMemberamrx:RSSolutionsMember2023-01-012023-06-300001723128amrx:SellingGeneralAndAdministrativeLogisticsServicesMemberamrx:RSSolutionsMember2022-01-012022-06-300001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2023-04-012023-06-300001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2022-04-012022-06-300001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2023-01-012023-06-300001723128amrx:MembersTaxReceivableAgreementMemberamrx:OtherExpenseTaxReceivableAgreementTRALiabilityMember2022-01-012022-06-300001723128us-gaap:RelatedPartyMemberamrx:RondoPartnersLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:RondoPartnersLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:KashivBioSciencesLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:KashivBioSciencesLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:AsanaBiosciencesLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:AsanaBiosciencesLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:ApaceKYLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:ApaceKYLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:AzaTechPharmaLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:AzaTechPharmaLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:AvtarInvestmentsLLCMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:AvtarInvestmentsLLCMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:SellersOfAvKARELLCAndRSMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:SellersOfAvKARELLCAndRSMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:MembersTaxReceivableAgreementMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:MembersTaxReceivableAgreementMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:RSSolutionsMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:RSSolutionsMember2022-12-310001723128amrx:AlkermesPlcMemberus-gaap:RelatedPartyMember2023-06-300001723128amrx:AlkermesPlcMemberus-gaap:RelatedPartyMember2022-12-310001723128us-gaap:RelatedPartyMemberamrx:AmnealGroupMember2023-06-300001723128us-gaap:RelatedPartyMemberamrx:AmnealGroupMember2022-12-31amrx:segment0001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2023-04-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2023-04-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2023-04-012023-06-300001723128us-gaap:CorporateNonSegmentMember2023-04-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2023-01-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2023-01-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2023-01-012023-06-300001723128us-gaap:CorporateNonSegmentMember2023-01-012023-06-300001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2022-04-012022-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2022-04-012022-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2022-04-012022-06-300001723128us-gaap:CorporateNonSegmentMember2022-04-012022-06-300001723128us-gaap:OperatingSegmentsMemberamrx:GenericsSegmentMember2022-01-012022-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AmnealSpecialtyPharmaSegmentMember2022-01-012022-06-300001723128us-gaap:OperatingSegmentsMemberamrx:AvKARESegmentMember2022-01-012022-06-300001723128us-gaap:CorporateNonSegmentMember2022-01-012022-06-3000017231282021-09-012021-09-01amrx:facility0001723128us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2023-07-012023-07-310001723128amrx:RondoTermLoanMemberus-gaap:SubsequentEventMember2023-07-012023-07-31

For the transition period from                        to                       

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐ 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

As of July 31, 2023, there were 154,194,960 shares of Class A common stock outstanding and 152,116,890 shares of Class B common stock outstanding, both with a par value of $0.01.

This Quarterly Report on Form 10-Q and Amneal Pharmaceuticals, Inc.’s other publicly available documents contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (“the Company”, “we”, “us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.

Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to:

•our ability to successfully develop, license, acquire and commercialize new products on a timely basis;

•the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices;

•our ability to obtain exclusive marketing rights for our products;

•our ability to manage our growth through acquisitions and otherwise;

•our revenues derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers;

•the continuing trend of consolidation of certain customer groups;

•our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods;

•our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness;

•our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness;

•our dependence on third-party agreements for a portion of our product offerings;

•legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives;

•risks related to federal regulation of arrangements between manufacturers of branded and generic products;

•our reliance on certain licenses to proprietary technologies from time to time;

•the significant amount of resources we expend on research and development;

•the risk of product liability and other claims against us by consumers and other third parties;

•risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws;

•changes to Food and Drug Administration product approval requirements;

•the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers;

•our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties;

•our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms;

•the impact of global economic, political or other catastrophic events, including recent events affecting the financial services industry;

•our ability to attract, hire and retain highly skilled personnel;

•our obligations under a tax receivable agreement may be significant;

•the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group; and

•such other factors as may be set forth elsewhere in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, particularly in the section 1A. Risk Factors and our public filings with the SEC.

Investors should carefully read our Annual Report on Form 10-K for the year ended December 31, 2022, including the section 1A. Risk Factors, for a description of certain risks that could, among other things, cause our actual results to differ materially from those expressed in our forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described herein and in our Annual Report to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. The Company operates principally in the United States (the “U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

The Company held 50.3% of Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held the remaining 49.7% as of June 30, 2023.

The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2022 included in the Company’s 2022 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023, cash flows for the six months ended June 30, 2023 and 2022 and the results of its operations, its comprehensive income (loss) and its changes in stockholders’ equity for the three and six months ended June 30, 2023 and 2022. The consolidated balance sheet data at December 31, 2022 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.

Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2022 Annual Report on Form 10-K.

The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023 and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements because the Company did not acquire a business during the three and six months ended June 30, 2023.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848, which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company adopted ASU 2020-04 during the three months ended June 30, 2023 (refer to Note 15. Debt and Note 18. Financial Instruments for additional information). The adoption of ASU 2020-04 did not have a material impact on the Company’s consolidated financial statements.

The prior period balance related to cost of goods sold impairment charges of $5.1 million, formerly included in a separate income statement caption for both the three and six months ended June 30, 2022, has been reclassified to be included within the income statement caption cost of goods sold to conform with the current period presentation.

The prior period balance related to loss on refinancing of $0.3 million, formerly included in a separate income statement caption for both the three and six months ended June 30, 2022, has been reclassified to be included within the income statement caption other income, net to conform to the current period presentation.

On December 30, 2021, the Company entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, “Saol”), a private specialty pharmaceutical company, pursuant to which it agreed to acquire Saol’s baclofen franchise, including Lioresal®, LYVISPAH™, and a pipeline product under development (the “Saol Acquisition”). The Saol Acquisition expanded the Company’s commercial institutional and specialty portfolio in neurology and added commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction closed on February 9, 2022. Consideration for the Saol Acquisition included $84.7 million, paid at closing with cash on hand, and contingent royalty payments based on annual net sales for certain acquired assets, beginning in June 2023.

Refer to Note 3. Acquisitions in the Company’s 2022 Annual Report on Form 10-K for additional information.

The Company recognizes revenue in accordance with ASC 606. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.

Refer to Note 5. Alliance and Collaboration for further information related to revenue recognition associated with a license agreement with multiple performance obligations.

The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue: